Where Is the Data? Delayed and Chronic irAE Surveillance and Management After Cessation of ICIs: Expert Insights From SITC on Survivorship Care and the Need for Long-Term Data

    March 2026 in “ Journal for ImmunoTherapy of Cancer ”
    Tessa Flores, Emily S. Tonorezos, Shailender Bhatia, Julie R. Brahmer, Laura C. Cappelli, Monica T. Cooper, Marianne Davies, Samantha Guild, Krishna S. Gunturu, John B A G Haanen, D. Johnson, Mario E. Lacouture, Rom S. Leidner, Sandra Mitchell, F. Perry Wilson, Javid J. Moslehi, Jarushka Naidoo, M. Obeid, Michael A. Postow, Igor Puzanov, Mary E. Reid, Bianca Santomasso, Dirk Schadendorf, Ann W. Silk, Ryan J Sullivan, Thomas Bolig, Xingru Li, Paolo A Ascierto, Marc S Ernstoff
    TLDR Long-term data and a team approach are needed to manage chronic side effects from cancer treatments.
    Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but present challenges due to immune-related adverse events (irAEs) that can be chronic or delayed. An Expert Panel from the Society for Immunotherapy of Cancer highlights the need for a comprehensive irAE registry and multidisciplinary care to manage these events effectively. Chronic irAEs, affecting up to 46.2% of patients, can lead to permanent organ dysfunction. The document emphasizes the importance of long-term data collection, clinician education, and a team-based approach to improve survivorship care. It calls for more research on biomarkers and standardized data collection to guide management strategies, proposing an international registry to enhance understanding and patient care.
    Discuss this study in the Community →